Servicegesellschaft Krankenhaus Waldfriede mbH

The trials here

What the 3 trials at this site are about, from their registry records.

Conditions

• Crohn's disease2 trials
• Ulcerative colitis1 trial

Phase

• Phase 22 trials
• Phase 31 trial

Status

• Completed2 trials
• Active, not recruiting1 trial

Lead sponsor

• AbbVie1 trial
• Agomab Spain S.L.U.1 trial
• Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)1 trial

Running trials

• Active, not recruiting

  Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)

  NCT04524611· Phase 3· AbbVie· Source

Closed trials

• Completed

  A clinical trial to assess the safety and effects of AGMB-129 compared to placebo in patients with fibrostenotic Crohn’s disease.

  2022-502789-26-01· Phase 2· Agomab Spain S.L.U.· Source

• Completed

  A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC

  NCT05611671· Phase 2· Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)· Source